NCT06992609
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06992609
Title Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. (ALBORAN)
Acronym ALBORAN
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP

Facility Status City State Zip Country Details
Research Site A Coruña 15006 Spain Details
Research Site Badajoz 06080 Spain Details
Research Site Barakaldo 48903 Spain Details
Research Site Barcelona 08035 Spain Details
Research Site Barcelona 08036 Spain Details
Research Site Barcelona 08907 Spain Details
Research Site Madrid 28041 Spain Details
Research Site Madrid 28046 Spain Details
Research Site Málaga 29010 Spain Details
Research Site Oviedo 33011 Spain Details
Research Site Santander 39008 Spain Details
Research Site Seville 41013 Spain Details
Research Site Valencia 46026 Spain Details
Research Site Zaragoza 50009 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field